NewLimit Raises $435 Million to Advance Cellular Reprogramming Research

NewLimit, a longevity biotech company co-founded by Coinbase chief executive Brian Armstrong, has raised $435 million in a Series C financing round, according to STAT News. The company announced the round on June 2, 2026.

The round was led by Founders Fund, with participation from investors including Thrive Capital, Lilly Ventures, and technologists Nat Friedman and Daniel Gross, STAT News reported. Co-founder and chief executive Jacob Kimmel put the company's valuation at $3.1 billion. STAT News noted the raise follows a $130 million Series B in May 2025 and an additional $45 million round in October 2025.

NewLimit was co-founded by Armstrong, Kimmel, a stem cell biologist who serves as chief executive, and Blake Byers, a former GV partner and bioengineer, according to the report. The company is based in South San Francisco.

NewLimit works on cellular reprogramming, an area of research that uses combinations of genes to shift cells toward a younger cellular state. According to reporting on the round, the company said a prototype medicine reversed measures of cellular age in old human liver cells in the laboratory, a preclinical finding that it said informed its decision to move toward the clinic. STAT News reported that the company plans a first clinical trial of a liver medicine, with proceeds from the round funding that effort. A specific trial start date was not detailed in the accessible reporting.

It is important to note that the liver-cell result described by the company is a laboratory finding and has not been shown to translate into a safe or effective treatment in people. Cellular reprogramming remains an experimental field, and NewLimit's candidate had not entered human testing as of the announcement. No efficacy in patients has been demonstrated.

The financing places NewLimit among the most heavily capitalized companies in the longevity sector. As with any early-stage therapeutic program, whether the company's approach benefits patients will depend on clinical results that have not yet been generated. Readers should consult qualified medical professionals before making health decisions and should not treat preclinical findings as evidence of a proven therapy.

This article summarizes reporting by STAT News. Figures, quotes, and details are attributed to that source.